NR 565 / NR565
Advanced Pharmacology
Midterm Edapt Review
Practice Questions and Study Guide — Already Rated A — 2026/2027 Edition
Chamberlain University
NR565 Advanced Pharmacology — Midterm Edapt Module Review
Aligned with NR565 Syllabus, Edapt Module Objectives & Advanced Practice Pharmacotherapeutics Standards
Total Questions 130 Multiple Choice
Sections 11 thematic modules
Cognitive Mix 25% Recall | 50% Application | 25% Analysis
Question Style 75% Scenario-Based | 25% Direct Knowledge
Format 4 options (A–D), one correct answer, with rationale
Special Inclusions 15 Edapt concepts | 12 drug interactions/CYP450 | 10 monitoring/ADR
Instructions: This comprehensive midterm Edapt review contains 130 multiple-choice questions
distributed across eleven thematic sections aligned with the Chamberlain NR565 Advanced
Pharmacology course syllabus and Edapt learning module objectives. Each question has exactly one
correct answer marked with *[CORRECT]*. A rationale follows each question, referencing the NR565
curriculum and Edapt module content. Use this guide for self-assessment, focused remediation, and
midterm examination preparation. Allow approximately 1 minute per question for timed practice (total
~2 hours for full review).
Examination Structure Overview
# Section Questions Cognitive Focus
Pharmacokinetics & Pharmacodynamics (Edapt
1 Q1–Q15 (15) Recall / Application
Modules)
2 Pharmacogenomics & Individualized Therapy Q16–Q25 (10) Application / Analysis
3 Prescriptive Authority, DEA Regulations, & Legal Q26–Q35 (10) Recall / Application
4 Cardiovascular Pharmacology Q36–Q55 (20) Application / Analysis
5 Respiratory & Pulmonary Pharmacology Q56–Q65 (10) Application / Analysis
6 Endocrine Pharmacology Q66–Q80 (15) Application / Analysis
Chamberlain University | NR565 Advanced Pharmacology | Midterm
Aligned
Edapt
with
Review
NR565 Syllabus, Edapt Modules & Advanced Practice Standards
,NR 565 / NR565 Advanced Pharmacology Midterm Edapt Review | Already Rated A | Latest, 2026/2027 | Chamberlain Page 2
7 Anti-Infective Pharmacology Q81–Q92 (12) Application / Analysis
8 CNS & Psychopharmacology Q93–Q106 (14) Application / Analysis
9 Pain Management & Anti-Inflammatory Agents Q107–Q116 (10) Application / Analysis
10 GI, Renal, & Genitourinary Pharmacology Q117–Q124 (8) Application / Analysis
Drug Interactions, Adverse Reactions, &
11 Q125–Q130 (6) Analysis / Application
Monitoring
COMPREHENSIVE MIDTERM EDAPT REVIEW — 130 QUESTIONS
Section 1: Pharmacokinetics & Pharmacodynamics (Edapt Modules) (15
Questions (Q1–Q15))
Q1: A patient receives oral morphine. Compared to IV morphine, the oral dose must be
substantially higher to achieve the same effect. Which pharmacokinetic concept best
explains this requirement?
A. Plasma protein binding
B. First-pass effect (hepatic metabolism before reaching systemic circulation) *[CORRECT]*
C. Renal tubular reabsorption
D. Volume of distribution
Correct Answer: B
Rationale: The first-pass effect describes hepatic metabolism of a fraction of drug before it reaches
systemic circulation when given orally, reducing bioavailability. IV dosing bypasses the portal circulation,
so a smaller IV dose achieves equivalent effect. Per NR565 Edapt modules, oral morphine bioavailability is
roughly 30% due to first-pass metabolism, necessitating higher oral doses. The other options describe
different pharmacokinetic concepts that do not primarily explain the oral/IV dose discrepancy.
Chamberlain University | NR565 Advanced Pharmacology | Midterm
Aligned
Edapt
with
Review
NR565 Syllabus, Edapt Modules & Advanced Practice Standards
,NR 565 / NR565 Advanced Pharmacology Midterm Edapt Review | Already Rated A | Latest, 2026/2027 | Chamberlain Page 3
Q2: A drug has a half-life of 12 hours. Approximately how long will it take to reach
steady-state plasma concentrations with consistent dosing?
A. 12 hours
B. 24 hours
C. 48-60 hours (4-5 half-lives) *[CORRECT]*
D. 120 hours
Correct Answer: C
Rationale: Steady state is achieved after approximately 4-5 half-lives of consistent dosing. For a drug with
a 12-hour half-life, steady state is reached in 48-60 hours. The NR565 Edapt pharmacokinetics module
emphasizes this principle for timing therapeutic drug monitoring and dose adjustments. Choosing 12
hours (one half-life) or 24 hours (two half-lives) is insufficient; 120 hours is excessive.
Q3: A patient with severe hepatic cirrhosis requires a medication that undergoes extensive
hepatic metabolism. Which pharmacokinetic change is most likely?
A. Increased first-pass metabolism, lower drug levels
B. Decreased metabolism and clearance, leading to drug accumulation and prolonged
half-life *[CORRECT]*
C. Increased protein binding, decreased free drug
D. No change in drug pharmacokinetics
Correct Answer: B
Rationale: Hepatic disease reduces drug-metabolizing capacity and plasma protein synthesis, leading to
decreased clearance, drug accumulation, and prolonged half-life. The NR565 Edapt module emphasizes
dose reduction and increased monitoring for hepatically cleared drugs in cirrhosis. Increased first-pass
metabolism (A) is incorrect because cirrhosis reduces metabolism. The other options mischaracterize the
impact of hepatic disease.
Q4: Which statement best distinguishes potency from efficacy?
A. Potency refers to the maximum effect a drug can produce; efficacy refers to the dose required
to produce an effect
B. Potency refers to the dose required to produce a given effect (EC50); efficacy refers to the
maximum effect a drug can produce (Emax) *[CORRECT]*
C. Potency and efficacy are interchangeable terms
D. Potency is determined by route of administration; efficacy by metabolism
Correct Answer: B
Rationale: Potency is the dose required to produce a given effect (reflected by EC50 on a dose-response
curve), while efficacy is the maximum effect a drug can produce (Emax). NR565 Edapt emphasizes that a
potent drug may have low efficacy and vice versa. The other options invert the definitions or conflate the
concepts.
Chamberlain University | NR565 Advanced Pharmacology | Midterm
Aligned
Edapt
with
Review
NR565 Syllabus, Edapt Modules & Advanced Practice Standards
, NR 565 / NR565 Advanced Pharmacology Midterm Edapt Review | Already Rated A | Latest, 2026/2027 | Chamberlain Page 4
Q5: A patient receives a drug with a narrow therapeutic index. Which implication is most
accurate?
A. The drug has a wide safety margin and requires minimal monitoring
B. The drug requires careful dosing and monitoring because the gap between minimum
effective concentration and toxic concentration is small *[CORRECT]*
C. The drug is safe at any dose
D. The drug cannot be prescribed in outpatient settings
Correct Answer: B
Rationale: A narrow therapeutic index means the difference between therapeutic and toxic
concentrations is small, requiring careful dosing and monitoring (e.g., lithium, warfarin, digoxin). The
NR565 Edapt module emphasizes therapeutic drug monitoring for such agents. The other options misstate
the safety implications of narrow therapeutic index.
Q6: A patient taking propranolol abruptly stops the medication and experiences
tachycardia, hypertension, and angina. Which pharmacodynamic mechanism best explains
this phenomenon?
A. Allergic reaction
B. Up-regulation of beta receptors during chronic blockade, producing exaggerated
response when agonist (endogenous catecholamines) is unopposed *[CORRECT]*
C. Pharmacokinetic enzyme induction
D. Idiosyncratic reaction
Correct Answer: B
Rationale: Chronic beta-blocker therapy causes up-regulation (increased number) of beta-adrenergic
receptors. Abrupt discontinuation leaves the up-regulated receptors exposed to endogenous
catecholamines, producing rebound tachycardia, hypertension, and ischemia. NR565 Edapt emphasizes
tapering beta-blockers to avoid this phenomenon. The other options do not explain receptor-mediated
withdrawal effects.
Chamberlain University | NR565 Advanced Pharmacology | Midterm
Aligned
Edapt
with
Review
NR565 Syllabus, Edapt Modules & Advanced Practice Standards
Advanced Pharmacology
Midterm Edapt Review
Practice Questions and Study Guide — Already Rated A — 2026/2027 Edition
Chamberlain University
NR565 Advanced Pharmacology — Midterm Edapt Module Review
Aligned with NR565 Syllabus, Edapt Module Objectives & Advanced Practice Pharmacotherapeutics Standards
Total Questions 130 Multiple Choice
Sections 11 thematic modules
Cognitive Mix 25% Recall | 50% Application | 25% Analysis
Question Style 75% Scenario-Based | 25% Direct Knowledge
Format 4 options (A–D), one correct answer, with rationale
Special Inclusions 15 Edapt concepts | 12 drug interactions/CYP450 | 10 monitoring/ADR
Instructions: This comprehensive midterm Edapt review contains 130 multiple-choice questions
distributed across eleven thematic sections aligned with the Chamberlain NR565 Advanced
Pharmacology course syllabus and Edapt learning module objectives. Each question has exactly one
correct answer marked with *[CORRECT]*. A rationale follows each question, referencing the NR565
curriculum and Edapt module content. Use this guide for self-assessment, focused remediation, and
midterm examination preparation. Allow approximately 1 minute per question for timed practice (total
~2 hours for full review).
Examination Structure Overview
# Section Questions Cognitive Focus
Pharmacokinetics & Pharmacodynamics (Edapt
1 Q1–Q15 (15) Recall / Application
Modules)
2 Pharmacogenomics & Individualized Therapy Q16–Q25 (10) Application / Analysis
3 Prescriptive Authority, DEA Regulations, & Legal Q26–Q35 (10) Recall / Application
4 Cardiovascular Pharmacology Q36–Q55 (20) Application / Analysis
5 Respiratory & Pulmonary Pharmacology Q56–Q65 (10) Application / Analysis
6 Endocrine Pharmacology Q66–Q80 (15) Application / Analysis
Chamberlain University | NR565 Advanced Pharmacology | Midterm
Aligned
Edapt
with
Review
NR565 Syllabus, Edapt Modules & Advanced Practice Standards
,NR 565 / NR565 Advanced Pharmacology Midterm Edapt Review | Already Rated A | Latest, 2026/2027 | Chamberlain Page 2
7 Anti-Infective Pharmacology Q81–Q92 (12) Application / Analysis
8 CNS & Psychopharmacology Q93–Q106 (14) Application / Analysis
9 Pain Management & Anti-Inflammatory Agents Q107–Q116 (10) Application / Analysis
10 GI, Renal, & Genitourinary Pharmacology Q117–Q124 (8) Application / Analysis
Drug Interactions, Adverse Reactions, &
11 Q125–Q130 (6) Analysis / Application
Monitoring
COMPREHENSIVE MIDTERM EDAPT REVIEW — 130 QUESTIONS
Section 1: Pharmacokinetics & Pharmacodynamics (Edapt Modules) (15
Questions (Q1–Q15))
Q1: A patient receives oral morphine. Compared to IV morphine, the oral dose must be
substantially higher to achieve the same effect. Which pharmacokinetic concept best
explains this requirement?
A. Plasma protein binding
B. First-pass effect (hepatic metabolism before reaching systemic circulation) *[CORRECT]*
C. Renal tubular reabsorption
D. Volume of distribution
Correct Answer: B
Rationale: The first-pass effect describes hepatic metabolism of a fraction of drug before it reaches
systemic circulation when given orally, reducing bioavailability. IV dosing bypasses the portal circulation,
so a smaller IV dose achieves equivalent effect. Per NR565 Edapt modules, oral morphine bioavailability is
roughly 30% due to first-pass metabolism, necessitating higher oral doses. The other options describe
different pharmacokinetic concepts that do not primarily explain the oral/IV dose discrepancy.
Chamberlain University | NR565 Advanced Pharmacology | Midterm
Aligned
Edapt
with
Review
NR565 Syllabus, Edapt Modules & Advanced Practice Standards
,NR 565 / NR565 Advanced Pharmacology Midterm Edapt Review | Already Rated A | Latest, 2026/2027 | Chamberlain Page 3
Q2: A drug has a half-life of 12 hours. Approximately how long will it take to reach
steady-state plasma concentrations with consistent dosing?
A. 12 hours
B. 24 hours
C. 48-60 hours (4-5 half-lives) *[CORRECT]*
D. 120 hours
Correct Answer: C
Rationale: Steady state is achieved after approximately 4-5 half-lives of consistent dosing. For a drug with
a 12-hour half-life, steady state is reached in 48-60 hours. The NR565 Edapt pharmacokinetics module
emphasizes this principle for timing therapeutic drug monitoring and dose adjustments. Choosing 12
hours (one half-life) or 24 hours (two half-lives) is insufficient; 120 hours is excessive.
Q3: A patient with severe hepatic cirrhosis requires a medication that undergoes extensive
hepatic metabolism. Which pharmacokinetic change is most likely?
A. Increased first-pass metabolism, lower drug levels
B. Decreased metabolism and clearance, leading to drug accumulation and prolonged
half-life *[CORRECT]*
C. Increased protein binding, decreased free drug
D. No change in drug pharmacokinetics
Correct Answer: B
Rationale: Hepatic disease reduces drug-metabolizing capacity and plasma protein synthesis, leading to
decreased clearance, drug accumulation, and prolonged half-life. The NR565 Edapt module emphasizes
dose reduction and increased monitoring for hepatically cleared drugs in cirrhosis. Increased first-pass
metabolism (A) is incorrect because cirrhosis reduces metabolism. The other options mischaracterize the
impact of hepatic disease.
Q4: Which statement best distinguishes potency from efficacy?
A. Potency refers to the maximum effect a drug can produce; efficacy refers to the dose required
to produce an effect
B. Potency refers to the dose required to produce a given effect (EC50); efficacy refers to the
maximum effect a drug can produce (Emax) *[CORRECT]*
C. Potency and efficacy are interchangeable terms
D. Potency is determined by route of administration; efficacy by metabolism
Correct Answer: B
Rationale: Potency is the dose required to produce a given effect (reflected by EC50 on a dose-response
curve), while efficacy is the maximum effect a drug can produce (Emax). NR565 Edapt emphasizes that a
potent drug may have low efficacy and vice versa. The other options invert the definitions or conflate the
concepts.
Chamberlain University | NR565 Advanced Pharmacology | Midterm
Aligned
Edapt
with
Review
NR565 Syllabus, Edapt Modules & Advanced Practice Standards
, NR 565 / NR565 Advanced Pharmacology Midterm Edapt Review | Already Rated A | Latest, 2026/2027 | Chamberlain Page 4
Q5: A patient receives a drug with a narrow therapeutic index. Which implication is most
accurate?
A. The drug has a wide safety margin and requires minimal monitoring
B. The drug requires careful dosing and monitoring because the gap between minimum
effective concentration and toxic concentration is small *[CORRECT]*
C. The drug is safe at any dose
D. The drug cannot be prescribed in outpatient settings
Correct Answer: B
Rationale: A narrow therapeutic index means the difference between therapeutic and toxic
concentrations is small, requiring careful dosing and monitoring (e.g., lithium, warfarin, digoxin). The
NR565 Edapt module emphasizes therapeutic drug monitoring for such agents. The other options misstate
the safety implications of narrow therapeutic index.
Q6: A patient taking propranolol abruptly stops the medication and experiences
tachycardia, hypertension, and angina. Which pharmacodynamic mechanism best explains
this phenomenon?
A. Allergic reaction
B. Up-regulation of beta receptors during chronic blockade, producing exaggerated
response when agonist (endogenous catecholamines) is unopposed *[CORRECT]*
C. Pharmacokinetic enzyme induction
D. Idiosyncratic reaction
Correct Answer: B
Rationale: Chronic beta-blocker therapy causes up-regulation (increased number) of beta-adrenergic
receptors. Abrupt discontinuation leaves the up-regulated receptors exposed to endogenous
catecholamines, producing rebound tachycardia, hypertension, and ischemia. NR565 Edapt emphasizes
tapering beta-blockers to avoid this phenomenon. The other options do not explain receptor-mediated
withdrawal effects.
Chamberlain University | NR565 Advanced Pharmacology | Midterm
Aligned
Edapt
with
Review
NR565 Syllabus, Edapt Modules & Advanced Practice Standards
